World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
66
Citations
14035
World Ranking
2778
National Ranking
64

Brian J. Ward publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Brian J. Ward sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 262 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Brian J. Ward D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Brian J. Ward sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 66 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Brian J. Ward is affiliated with the McGill University Health Centre in Canada. Their research output encompasses a significant number of publications within the field of Medicine, particularly focusing on Infectious Diseases and Epidemiology. Their work extends to related subfields such as Biotechnology, Physiology, and Health.

Ward's main research topics include:

  • SARS-CoV-2 and COVID-19 Research
  • Transgenic Plants and Applications
  • Viral gastroenteritis research and epidemiology
  • Vaccine Coverage and Hesitancy
  • Smoking Behavior and Cessation
  • Influenza Virus Research Studies
  • Global Public Health Policies and Epidemiology

Frequent co-authors who have contributed alongside Ward consist of:

  • Constantine Vardavas
  • Witold Zatoński
  • Antigona Trofor
  • Ute Mons
  • Tibor Demjén

Ward has published extensively in several journals. Primary publication venues include:

  • Vaccine
  • European Journal of Public Health
  • bioRxiv (Cold Spring Harbor Laboratory)
  • npj Vaccines
  • PLoS ONE

Notable recent papers by Brian J. Ward include:

  • Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19, 2021, Nature Medicine
  • Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials, 2020, The Lancet
  • Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age, 2021, Vaccine

The research topics covered by these papers reflect Ward's focus on vaccine development, virus-like particle technology, and vaccine safety and efficacy. The convergence of plant biotechnology with vaccine research is evident in their work on plant-derived virus-like particle vaccines.

Best Publications

  • Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival

    Peter J Iliff;Ellen G Piwoz;Naume V Tavengwa;Clare D Zunguza

  • Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

    Marc-André D’Aoust;Pierre-Olivier Lavoie;Manon M.-J. Couture;Sonia Trépanier

  • Child mortality according to maternal and infant HIV status in Zimbabwe.

    Edmore Marinda;Jean H. Humphrey;Peter J. Iliff;Kuda Mutasa

  • Differential CD4 T Cell Activation in Measles

    Diane E. Griffin;Brian J. Ward

  • Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza

    Nathalie Landry;Brian J. Ward;Sonia Trépanier;Emanuele Montomoli

  • Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.

    Brian J Ward;Philipe Gobeil;Annie Séguin;Judith Atkins

  • Infection of Monocytes during Measles

    Lisa M. Esolen;Brian J. Ward;Thomas R. Moench;Diane E. Griffin

  • Successful Treatment of Drug-Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator

    Iracema Arevalo;Brian Ward;Richard Miller;Tze-Chiang Meng

  • Immune Activation in Measles

    Diane E. Griffin;Brian J. Ward;Enrique Jauregui;Richard T. Johnson

  • Effects of a Single Large Dose of Vitamin A, Given during the Postpartum Period to HIV-Positive Women and Their Infants, on Child HIV Infection, HIV-Free Survival, and Mortality

    Jean H. Humphrey;Peter J. Iliff;Edmore T. Marinda;Kuda Mutasa

  • Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response

    Brian J. Ward;Diane E. Griffin

  • Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay.

    John W Hargrove;Jean H Humphrey;Kuda Mutasa;Bharat S Parekh

  • Comparison of Blood Smear, Antigen Detection, and Nested-PCR Methods for Screening Refugees from Regions Where Malaria Is Endemic after a Malaria Outbreak in Quebec, Canada

    Momar Ndao;Etienne Bandyayera;Evelyne Kokoskin;Theresa W. Gyorkos

  • Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

    Brian J Ward;Alexander Makarkov;Annie Séguin;Stéphane Pillet

  • Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

    Scott A. Halperin;Brian Ward;Curtis Cooper;Gerald Predy

  • Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.

    C. Miranda-Verástegui;A. Llanos-Cuentas;I. Arévalo;B.J. Ward

  • A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.

    Stéphane Pillet;Éric Aubin;Sonia Trépanier;Diane Bussière

  • Cellular Immunity in Measles Vaccine Failure: Demonstration of Measles Antigen-Specific Lymphoproliferative Responses despite Limited Serum Antibody Production after Revaccination

    B. J. Ward;N. Boulianne;S. Ratnam;M.-C. Guiot

  • Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy.

    Ai Koyanagi;Jean H. Humphrey;Robert Ntozini;Kusum Nathoo

  • Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study.

    Jean H Humphrey;Edmore Marinda;Kuda Mutasa;Lawrence H Moulton

  • Immune Activation during Measles: Interferon-γ and Neopterin in Plasma and Cerebrospinal Fluid in Complicated and Uncomplicated Disease

    Diane E. Griffin;Brian J. Ward;Brian J. Ward;Enrique Jauregui;Enrique Jauregui;Richard T. Johnson

Frequent Co-Authors

Scott A. Halperin
Scott A. Halperin Dalhousie University
David W. Scheifele
David W. Scheifele University of British Columbia
Lawrence H. Moulton
Lawrence H. Moulton Johns Hopkins University
Shelly A. McNeil
Shelly A. McNeil Dalhousie University
Michel Roger
Michel Roger University of Montreal
Marc Dionne
Marc Dionne Université Laval
Gaston De Serres
Gaston De Serres Université Laval
Kevin C. Kain
Kevin C. Kain University Health Network
Danuta M. Skowronski
Danuta M. Skowronski University of British Columbia
Mark Loeb
Mark Loeb McMaster University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields offer diverse online degree options that can complement or expand your expertise. Transitioning from one nursing role to another is common, and programs like the fnp to acute care np bridge program provide a streamlined path for nurse practitioners looking to specialize further.

Accelerated programs are particularly popular among motivated students aiming to fast-track their careers. Exploring accelerated np programs can help you identify high-quality, time-efficient options that align with your goals in advanced nursing practice.

If you're starting without a nursing background, consider enrolling in online absn programs for non nurses. These accelerated bachelor programs make it possible to transition into nursing quickly while balancing other commitments.

Lastly, for those seeking less competitive entry, the easiest accelerated nursing programs to get into can offer accessible routes to obtaining a Bachelor of Science in Nursing. These options widen the path for aspiring healthcare professionals aiming to contribute to immunology and related fields.

Best Scientists Citing Brian J. Ward

Trending Scientists

Recently Published Articles